The comparative study on safety and effectiveness of restorative treatments for facial lipoatrophy associated with HIV

Facial Lipoatrophy associated with HIV is one of the worst adverse effects of HIV and antiviral treatments which not only impacts the quality of life by impairing self-esteem of the HIV infected patients but also is one of the most complex challenges of the family members and the community to adjust with the patient's social situation. Thymidine based nucleoside analog cessation is the only proven treatment for HIV associated lipoatrophy, although plastic surgeons and dermatologists are constantly exploring the new horizons of cosmetic procedures to restore the lost fat and maintain the normal and natural look of the HIV infected patients. Autologous fat transfer, biodegradable or permanent injectable fillers and facial prosthetics have been used for HIV facial lipoatrophy treatment and all have offered some acceptable safety and aesthetic results but apparently there are not sufficient clinical studies in treatment of choice in facial lipoatrophy for HIV infected patients. In this article we discuss the comparative efficacy of different therapies, assessment of existence and severity of facial lipoatrophy and treatment measures of various cosmetic procedures for HIV associated facial lipoatrophy.

Biography

Ali Khalifeh is a Board-Certified Dermatologist (YSMU), Board-Certified and Licensed Holistic Health Practitioner, specialized in Cosmetic Dermatology, Laser and Aesthetic Medicine. He is currently a President and Chief Director of the Canadian Association of Cosmetic Dermatology and Surgery and Teaching Professor of Medical Aesthetics Technology Program in CAMACS. He is serving as an Editorial Board Member of Journal of Clinical Research in Dermatology, Symbiosis Publishing. He is also the President of Bioptima Medicals Inc., Pharmaceutical and Cosmeceutical Company in Canada.

dr_akhalifeh@yahoo.com